Abeona Therapeutics Inc. — 2016 Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended December 31, 2016; it does not provide standalone fourth-quarter results. Abeona is a clinical-stage biopharmaceutical company developing gene therapies for rare genetic diseases. Its lead programs target Sanfilippo syndrome (ABO-101 and ABO-102). Other programs include gene therapies for Batten disease, Fanconi anemia and epidermolysis bullosa, as well as a plasma-derived therapy platform and marketed MuGard, commercialized through licensees.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Total revenue | $889,000 | $1,040,000 |
| Research and development expense | $10.655 million | $4.715 million |
| General and administrative expense | $13.290 million | $14.320 million |
| Total operating expenses | $24.770 million | $19.586 million |
| Operating loss | $23.881 million | $18.546 million |
| Net loss | $21.873 million | $14.526 million |
| Basic and diluted loss per share | $0.64 | $0.53 |
| Cash and cash equivalents at year-end | $69.142 million | $40.138 million |
| Working capital at year-end | $61.125 million | $39.091 million |
| Net cash used in operating activities | $13.014 million | $10.423 million |
MuGard royalties were $287,000, down from $438,000; license revenue was $602,000 in each year. The filing does not report a meaningful positive operating margin; operations were loss-making. Cash flows from investing activities were negative $519,000 in 2016, while financing activities provided $42.537 million. The November 2016 stock offerings generated approximately $44.057 million gross and $41.068 million net proceeds. Year-end total liabilities were $11.960 million, including a $4.000 million current payable to Plasma Technologies, LLC; the filing reports no separate interest-bearing debt balance.
Material changes versus 2015
- Net loss increased by $7.347 million, while total operating expenses rose by $5.184 million. R&D spending more than doubled, principally due to ABO-102 and other gene-therapy development, clinical preparation, and added scientific staff.
- G&A expense declined by $1.030 million, primarily from lower investor-relations, stock-based compensation and legal costs, partly offset by higher compensation and other expenses.
- Cash increased by $29.004 million, chiefly reflecting equity financing. Common shares issued and outstanding increased during the year.
- Miscellaneous and interest income fell to $2.014 million from $4.026 million. The 2016 amount included contingent-milestone settlement/revaluation and other settlements; it is not recurring product revenue.
Outlook, developments and principal risks
- Management expects continuing operating losses and substantial R&D spending for the next several years. No quantified revenue, earnings, cash-burn or product-launch guidance is provided, and the filing says future spending and project timing cannot be reliably predicted.
- During 2016, ABO-102 entered a Phase 1/2 trial, ABO-101 received FDA IND clearance, and EB-101 advanced in clinical development. ABO-102 received FDA Fast Track designation and orphan-drug designations were reported for lead programs. These designations do not assure approval or commercial success.
- Post-year-end updates disclosed early ABO-102 trial observations, including tolerability and biomarker changes in small cohorts. These are preliminary findings, not evidence of established efficacy. The filing also reports 2017 management and board changes and a Nasdaq notice concerning the independent-director majority requirement, with a cure deadline of July 10, 2017.
- A $4.000 million amount owed to Plasma Technologies was reclassified as current and was under negotiation; the agreement permits cash or stock payment. The company also reported a separate $1.200 million agreed payment for partial achievement of an acquisition milestone.
- Key risks include clinical and regulatory failure or delay, the need for additional capital and potential dilution, dependence on licensors and third-party manufacturers and trial operators, competition, reimbursement uncertainty, intellectual-property disputes, and the possibility that licensed products will not generate material revenue. The company specifically identified a third-party AAV9 patent that may require a license before ABO-101 or ABO-102 commercialization.
- The accumulated deficit was $332.473 million. The company reported no material pending legal proceedings, no impairment of licensed technology or goodwill in 2016, effective disclosure controls and internal control over financial reporting, and an unqualified audit opinion on its financial statements.
Important facts for investors to verify
- Current cash runway and projected clinical-development cash needs; the filing does not provide a clear runway estimate.
- Resolution and payment form for the $4.000 million Plasma Technologies obligation, and any resulting effects on liquidity or dilution.
- Updated enrollment, safety, efficacy, and regulatory timelines for ABO-102, ABO-101, EB-101 and other pipeline programs.
- License rights, milestone obligations and potential royalty burdens, including any AAV9 patent license required for commercialization.
- Whether MuGard royalties or other partner revenues can grow, given the low revenue base and declining royalties in 2016.
- Progress in restoring Nasdaq board-independence compliance after the January 2017 notice and the reported director resignation.